Generalized Anxiety Disorder (GAD) Clinical Trial
Official title:
Safety and Efficacy of Synchronized Transcranial Magnetic Stimulation (sTMS) for the Treatment of Generalized Anxiety Disorder (GAD) -An Open Label Investigator Initiated Trial
This clinical trial is an investigator-initiated open label study designed to evaluate the safety and efficacy of sTMS in subjects with Generalized Anxiety Disorder.
Subjects will receive 5 daily treatments per treatment week for 4 weeks (20 treatments).
Patients who do not meet a 50% reduction of Hamilton Anxiety Rating Scale (HAM-A) score
(non-responders) at 4 weeks will be offered 2 additional treatment weeks for up to 30
treatments total.
Subjects who qualify for enrollment will be followed and assessed using the: Mini
International Neuropsychiatric Interview (MINI) for Axis 1, Montreal Cognitive Assessment
(MoCA), Hamilton Anxiety Rating Scale (HAM-A), Hamilton Depression Rating Scale (HAM-D17),
Generalized Anxiety Disorder 7-item (GAD-7), and Quick Inventory of Depressive Symptomatology
Self Report (QIDS-SR16) patient reported scale. Treatment will be initiated on Day 1 of the
study and will be continued for a minimum of 4 and a maximum of 6 weeks.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01470469 -
SPD503 in Subjects Aged 6-17 Years With Generalized Anxiety Disorder (GAD), Separation Anxiety Disorder (SAD), or Social Phobia (SoP)
|
Phase 2 | |
| Completed |
NCT02305797 -
EDG004 Treatment of Adult Patients With Generalized Anxiety Disorder (GAD)
|
Phase 3 | |
| Completed |
NCT02662803 -
Clinical, Neurophysiological and Neuroendocrine Effects of Aerobe Exercise in Generalized Anxiety Disorder (GAD)
|
N/A | |
| Active, not recruiting |
NCT05738850 -
Study to Assess Adverse Events and How ABBV-932 Oral Capsules Moves Through the Body of Healthy Adult Participants
|
Phase 1 | |
| Recruiting |
NCT06024239 -
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of ABBV-932 in Healthy Adult Participants, Participants With Generalized Anxiety Disorder (GAD) and Participants With Bipolar Disorder (BPD)
|
Phase 1 |